Pulsed Field Ablation for Ventricular Tachycardia After Heart Attack
This study, called ASCEND, is looking at a new way to treat ventricular tachycardia (VT), a fast and irregular heartbeat, in people who have had a heart attack. It compares a new treatment called Pulsed Field Ablation (PFA) using the FARAPOINT catheter to the standard treatment, Radiofrequency Ablation (RFA), using catheters like FlexAbility or ThermoCool ST. The study wants to see if PFA is more effective at treating VT while being just as safe as RFA. You might be able to join if you are 18 or older, have ischemic heart disease (heart disease due to narrowed arteries) from a past heart attack, and have a certain heart pumping strength (ejection fraction) and documented sustained VT. The study aims to enroll 40 participants.
- Study design
- This is a pilot study that will randomly assign 40 participants to receive either Pulsed Field Ablation (PFA) or Radiofrequency Ablation (RFA). It is an open-label study, meaning both you and your doctors will know which treatment you are receiving.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure procedural safety within 7 days after the procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
At a glance
Conditions
NCT06891456
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cleveland Clinic
Cleveland, Ohiostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Pasquale Santangeli, MD, PhD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Procedural EfficiencyPeriprocedural
Total ablation time (in seconds) needed to achieve complete elimination of late abnormal ventricular activities (LAVAs) in myocardial scar.
- Procedural SafetyWithin 7 days post procedure
Count of individuals who experience any of the following: * Cardiac perforation * Pericardial effusion with hemodynamic compromise or needing intervention * New complete heart block * Coronary spasm * Acute MI * New acute severe mitral regurgitation or aortic regurgitation * Deep venous thrombosis * Vascular injury requiring surgical or percutaneous intervention * Pulmonary embolism * Stroke * Acute kidney injury * Death